Agreements

Date: 2017-05-02

Type of information: Licensing agreement

Compound: lentiviral vector platform

Company: Bluebird bio (USA - MA) GSK (UK)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement: licensing - commercialisation

Action mechanism: gene therapy

Disease: Wiscott-Aldrich syndrome, metachromatic leukodystrophy

Details:

• • On May 2, 2017, bluebird bio announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GSK Intellectual Property Development Limited.
• Under the terms of the agreement, GSK will non-exclusively license certain bluebird patent rights related to lentiviral vector technology to develop and commercialize gene therapies for Wiscott-Aldrich syndrome and metachromatic leukodystrophy, two rare genetic diseases.

Financial terms: Financial terms of the agreement include an upfront payment to bluebird as well as potential development and regulatory milestone payments and low single digit royalties on net sales of covered products.

Latest news:

Is general: Yes